MX2019013160A - Metodos de tratamiento selectivo del asma usando antagonistas de il-17. - Google Patents
Metodos de tratamiento selectivo del asma usando antagonistas de il-17.Info
- Publication number
- MX2019013160A MX2019013160A MX2019013160A MX2019013160A MX2019013160A MX 2019013160 A MX2019013160 A MX 2019013160A MX 2019013160 A MX2019013160 A MX 2019013160A MX 2019013160 A MX2019013160 A MX 2019013160A MX 2019013160 A MX2019013160 A MX 2019013160A
- Authority
- MX
- Mexico
- Prior art keywords
- antagonists
- methods
- treating asthma
- selectively treating
- asthma
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
- G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762501806P | 2017-05-05 | 2017-05-05 | |
| PCT/IB2018/053106 WO2018203289A1 (en) | 2017-05-05 | 2018-05-04 | Methods of selectively treating asthma using il-17 antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019013160A true MX2019013160A (es) | 2020-02-05 |
Family
ID=62245372
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019013160A MX2019013160A (es) | 2017-05-05 | 2018-05-04 | Metodos de tratamiento selectivo del asma usando antagonistas de il-17. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10676522B2 (https=) |
| EP (1) | EP3619536A1 (https=) |
| JP (1) | JP2020518604A (https=) |
| KR (1) | KR20190142398A (https=) |
| CN (1) | CN110582702A (https=) |
| AU (1) | AU2018263159A1 (https=) |
| BR (1) | BR112019023141A2 (https=) |
| CA (1) | CA3062179A1 (https=) |
| CL (1) | CL2019003161A1 (https=) |
| MX (1) | MX2019013160A (https=) |
| RU (1) | RU2019139387A (https=) |
| TW (1) | TW201842933A (https=) |
| WO (1) | WO2018203289A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3689907A1 (en) * | 2019-01-31 | 2020-08-05 | Numab Therapeutics AG | Antibodies targeting il-17a and methods of use thereof |
| CA3174345A1 (en) * | 2020-04-17 | 2021-10-21 | Eli Lilly And Company | Treatment of acute respiratory distress syndrome with anti-il17 antibodies |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0308324D0 (en) | 2003-04-10 | 2003-05-14 | Piezoptic Ltd | A chemical sensing device |
| CN1898564A (zh) * | 2003-12-24 | 2007-01-17 | 惠氏公司 | 治疗哮喘的方法 |
| GB0417487D0 (en) | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
| GB0425569D0 (en) | 2004-11-19 | 2004-12-22 | Celltech R&D Ltd | Biological products |
| CN101326195B9 (zh) | 2005-12-13 | 2022-11-11 | 伊莱利利公司 | 抗il-17抗体 |
| GB0612928D0 (en) | 2006-06-29 | 2006-08-09 | Ucb Sa | Biological products |
| US7833527B2 (en) | 2006-10-02 | 2010-11-16 | Amgen Inc. | Methods of treating psoriasis using IL-17 Receptor A antibodies |
| EP2631302A3 (en) | 2008-03-31 | 2014-01-08 | Genentech, Inc. | Compositions and methods for treating and diagnosing asthma |
| JP5581323B2 (ja) | 2008-09-29 | 2014-08-27 | ロシュ グリクアート アクチェンゲゼルシャフト | ヒトｉｌ１７に対する抗体およびその使用 |
| LT2953969T (lt) * | 2013-02-08 | 2019-12-10 | Novartis Ag | Anti-il-17a antikūnai ir jų panaudojimas autoimuninių ir uždegiminių ligų gydymui |
| SG11201603127WA (en) * | 2013-10-23 | 2016-05-30 | Genentech Inc | Methods of diagnosing and treating eosinophilic disorders |
| US20160000936A1 (en) * | 2014-06-10 | 2016-01-07 | Abbvie Inc. | Biomarkers for inflammatory disease and methods of using same |
| MX2017003216A (es) * | 2014-09-10 | 2017-05-23 | Novartis Ag | Uso de antagonistas de il-17 para inhibir la progresion del daño estructural en pacientes con artritis psoriasica. |
| GB201508832D0 (en) | 2015-05-22 | 2015-07-01 | Novartis Ag | A method for detecting an analyte |
-
2018
- 2018-05-03 US US15/969,952 patent/US10676522B2/en active Active
- 2018-05-03 TW TW107114983A patent/TW201842933A/zh unknown
- 2018-05-04 EP EP18727435.2A patent/EP3619536A1/en not_active Withdrawn
- 2018-05-04 JP JP2019560115A patent/JP2020518604A/ja active Pending
- 2018-05-04 CN CN201880029544.7A patent/CN110582702A/zh active Pending
- 2018-05-04 RU RU2019139387A patent/RU2019139387A/ru not_active Application Discontinuation
- 2018-05-04 CA CA3062179A patent/CA3062179A1/en not_active Abandoned
- 2018-05-04 KR KR1020197035578A patent/KR20190142398A/ko not_active Abandoned
- 2018-05-04 AU AU2018263159A patent/AU2018263159A1/en not_active Abandoned
- 2018-05-04 MX MX2019013160A patent/MX2019013160A/es unknown
- 2018-05-04 BR BR112019023141-2A patent/BR112019023141A2/pt not_active Application Discontinuation
- 2018-05-04 WO PCT/IB2018/053106 patent/WO2018203289A1/en not_active Ceased
-
2019
- 2019-11-04 CL CL2019003161A patent/CL2019003161A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3619536A1 (en) | 2020-03-11 |
| CN110582702A (zh) | 2019-12-17 |
| JP2020518604A (ja) | 2020-06-25 |
| KR20190142398A (ko) | 2019-12-26 |
| RU2019139387A (ru) | 2021-06-07 |
| BR112019023141A2 (pt) | 2020-07-28 |
| US20180319881A1 (en) | 2018-11-08 |
| US10676522B2 (en) | 2020-06-09 |
| WO2018203289A1 (en) | 2018-11-08 |
| TW201842933A (zh) | 2018-12-16 |
| CA3062179A1 (en) | 2018-11-08 |
| AU2018263159A1 (en) | 2019-11-07 |
| CL2019003161A1 (es) | 2020-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201491011A1 (ru) | Способы лечения с помощью ингибитора гамма-интерферона | |
| PH12019502331A1 (en) | Treatment of asthma with anti-tslp antibody | |
| NZ743124A (en) | Antibodies targeting fc receptor-like 5 and methods of use | |
| JOP20200309A1 (ar) | أجسام مضادة لـ il-11 | |
| PH12018500810A1 (en) | Antibody agents specific for human cd19 and uses thereof | |
| HK1250752A1 (zh) | 治疗骨髓增生性障碍的方法 | |
| EA201690746A1 (ru) | Лечение с применением ингибиторов тирозинкиназы брутона и иммунотерапии | |
| MY163057A (en) | Means and methods for trating dlblcl | |
| MX2021002728A (es) | Combinacion de anticuerpos anti-gen 3 de la activacion del linfoncito (lag-3) y anticuerpos anti-muerte celular programada 1 (pd-1) para usarse en el tratamiento de tumores. | |
| ZA202005388B (en) | Methods of treating ulcerative colitis | |
| MY196858A (en) | Method | |
| PH12015500196B1 (en) | Methods of treating a tauopathy | |
| EA201691683A1 (ru) | Антитела против dll3 и конъюгаты антитело-лекарственное средство для применения при меланоме | |
| WO2014138429A3 (en) | Peptidomimetic macrocycles and use thereof in regulating hif1alpha | |
| MX2019015604A (es) | Anticuerpos anti-tau y usos de los mismos en el tratamiento de una tauopatia. | |
| UA117556C2 (uk) | Спосіб збільшення ефективності терапевтичного засобу шляхом введення метотрексату | |
| PH12016500753A1 (en) | Antibodies specific to fcrn | |
| EA201790439A1 (ru) | Способы лечения множественной миеломы с применением иммуномодулирующих соединений в комбинации с антителами | |
| PH12018501443A1 (en) | Methods of administering hepcidin | |
| EA201790563A1 (ru) | Применение реслизумаба для лечения эозинофильной астмы со степенью тяжести от умеренной до тяжелой | |
| MX2025003476A (es) | Anticuerpos anti-il-27 y usos de los mismos | |
| EA202090260A1 (ru) | Средства и способы для генотерапии aav у человека | |
| MX2019013160A (es) | Metodos de tratamiento selectivo del asma usando antagonistas de il-17. | |
| EA201992875A1 (ru) | T-клетки со сниженным поверхностным фукозилированием и способы их получения и применения | |
| PH12019501358A1 (en) | Methods of administering hepcidin |